Annals of oncology : official journal of the European Society for Medical Oncology
Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors.
Y Zhu, S Jiang, Y Shi, S Wang, F Yuan, F Zhou, K Jiang, X Zhang, L Seneviratne, G Yu, M Zhang, T Liu, X Li, X Chen, X Wang
Published: 202510.1016/j.annonc.2025.11.013
Abstract
BACKGROUND: Trophoblast cell-surface antigen 2 (TROP2) is overexpressed in advanced or metastatic urothelial cancer (UC), representing a promising therapeutic target. Sacituzumab tirumotecan (sac-TMT) is a TROP2-directed antibody-drug conjugate with…
Preview only. Read the full abstract at the source